New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome

New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome

Currently, therapeutic tactics in patients with myelodysplastic syndrome is based on risk-adapted therapy followed by allogeneic hematopoietic stem cell transplantation, which remains the only radical method of treatment. for patients who cannot undergo transplantation, the problem of finding new me...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Morozova, N. Yu. Tsvetkov, M. V. Barabanshchikova, K. S. Yurovskaya, I. S. Moiseev
Format: Article
Language:Russian
Published: ABV-press 2022-11-01
Series:Онкогематология
Subjects:
myelodysplastic syndrome
hypomethylating agents
tim3
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/594
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items